Russia to test new COVID-19 antibody drug in new year | Inquirer News

Russia to test new COVID-19 antibody drug in new year

/ 09:58 PM December 28, 2020

FILE PHOTO: Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology, attends an interview with Reuters in Moscow, Russia September 24, 2020. REUTERS/Tatyana Makeyeva

 

 

ADVERTISEMENT

MOSCOW — Russia will begin trials of an antibody treatment for COVID-19 patients next year, the head of the Moscow institute that developed the country’s first vaccine against the new disease, Sputnik V, said on Monday.

Alexander Gintsburg, director of the Gamaleya Institute, was cited by the RIA news agency as saying that he hoped trials for the new antibody-based drug would begin in the autumn of 2021.

FEATURED STORIES

“I hope clinical trials will begin in autumn,” he said. “We need to develop this drug using several technologies at the same time, which is something that is being done right now.”

Russia has been asking COVID-19 patients to donate blood plasma, which is rich in antibodies, for research.

Earlier this year, U.S. President Donald Trump was treated with an experimental antibody cocktail for COVID-19 produced by drug maker Regeneron Pharmaceuticals Inc.

Antibodies are proteins made by the body’s immune system that latch on to and neutralize an invading virus. Regeneron’s cocktail contains an antibody made by the company and a second isolated from humans who recovered from COVID-19.

Gamaleya’s Gintsburg said on Sunday that the new Russian drug would be made up of “monoclonal antibodies,” genetically engineered versions of the antibodies that are found in the blood plasma of those who have been sick with COVID-19, the TASS news agency reported.

Russia last week stopped taking in new volunteers for its main human trial of Sputnik V, with developers saying it was unethical to administer a placebo to participants now that the shot was increasingly available to the public.

Russia began inoculating small numbers of people in high-risk groups soon after it granted regulatory approval to the vaccine in August. It launched its large-scale, final-stage trial in Moscow the following month.

The rollout ramped up this month and more than 200,000 Russians have now received the shot.

/MUF

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: antibody, COVID-19, Gamaleya Institute, Russia, Sputnik V, Test
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.